<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440112</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00360361-A</org_study_id>
    <secondary_id>R01NS099535</secondary_id>
    <nct_id>NCT03440112</nct_id>
  </id_info>
  <brief_title>Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin Arm</brief_title>
  <acronym>GABA-A</acronym>
  <official_title>Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolaas Bohnen, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The arm of this study evaluates possible GABA-A receptor target engagement effects of the
      FDA-approved medication, clarithromycin, in the setting of Parkinson's disease. Two-thirds of
      the subjects will receive clarithromycin for 7-9 days, and 1/3 will receive a placebo.
      [11C]Flumazenil GABA-A receptor PET imaging will be used to assess target engagement effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study focuses on neurochemical changes in the brain that occur in Parkinson's disease.
      In particular we will be looking a neurotransmitter called GABA. In some Parkinson's disease
      patients we see too much GABA activity in the brain. There is emerging in vitro and in vivo
      evidence that clarithromycin, an FDA-approved and orally available macrolide antibiotic, can
      act as a negative allosteric modulator of brain GABA-A receptors. This target engagement
      study examines the target engagement effect of GABA-A receptor modulation by clarithromycin.
      [11C]-flumazenil Positron Emission Tomography (PET) imaging results will be used to assess
      for possible GABA-A receptor target engagement effects of clarithromycin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participant, Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in [11-Carbon]-flumazenil ([11C]FMZ) PET Binding</measure>
    <time_frame>7-9 days</time_frame>
    <description>We will use brain PET imaging to assess quantitative changes in GABA-A receptors before and after the administration of clarithromycin in Parkinson disease subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quantitative biomechanics</measure>
    <time_frame>7-9 days</time_frame>
    <description>We will use the PIGD-UPDRS motor scale to assess axial motor functions before and after 7 days of clarithromycin and correlate this with the [11C]FMZ PET binding study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin (generic) capsule 250mg each</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose in a gel capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parkinson's disease (PD): PD diagnosis will follow the UK Parkinson's Disease Society
             Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD.

          2. Hoehn and Yahr stages 2-4

          3. Absence of dementia confirmed by cognitive testing.

          4. Abnormal 11C-Dihydrotetrabenazine ([11c]-DTBZ) PET study to demonstrate nigrostriatal
             dopaminergic denervation

        Exclusion Criteria:

          1. PD with Dementia (PDD) or dementia with Lewy bodies (DLB).

          2. Other disorders which may resemble PD, such as vascular dementia, normal pressure
             hydrocephalus, multiple system atrophy, corticobasal ganglionic degeneration, or toxic
             causes of parkinsonism. Prototypical cases have distinctive clinical profiles, like
             early and severe dysautonomia or appendicular apraxia, which may differentiate them
             from idiopathic PD. The use of the UKPDSBRC clinical diagnostic criteria for PD will
             mitigate the inclusion of subjects with atypical parkinsonism.

          3. Subjects on benzodiazepine, GABAB-ergic medications (baclofen, tizanidine),
             neuroleptic, anticholinergic (trihexphenidyl, benztropine), or cholinesterase
             inhibitor drugs.

          4. Evidence of a mass lesion on structural brain imaging (MRI).

          5. Participants in whom MRI is contraindicated including, but not limited to, those with
             a pacemaker, presence of metallic fragments near the eyes or spinal cord, chest, or
             cochlear implant.

          6. Severe claustrophobia precluding MR or PET imaging.

          7. Subjects limited by participation in research procedures involving ionizing radiation.

          8. Pregnancy (urine or serum pregnancy test within 48 hours of each PET session) or
             breastfeeding.

          9. History of seizures

         10. Significant anxiety or history of panic disorder.

         11. History of recent suicide attempt or overdose of tricyclic antidepressants or other
             medications

         12. Any other medical history determined by investigators to preclude safe participation.

        Exclusion criteria specific for clarithromycin arm of the study

          1. Allergy or hypersensitivity to clarithromycin, other macrolide antibiotics, or similar
             medicines such as azithromycin, erythromycin or telithromycin.

          2. History of significant atrial or ventricular arrhythmias.

          3. Significant liver or kidney disease.

          4. Corrected QT interval (QTc) prolongation.

          5. Subjects taking digoxin, colchicine, pimozide, cisapride, quetiapine, astemizole,
             terfenadine, ergotamine, or dihydroergotamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas I Bohnen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Minderovic, BS</last_name>
    <phone>734-998-8400</phone>
    <email>cmindero@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Dowling, MD</last_name>
    <phone>734-998-8400</phone>
    <email>cdowling@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muller</last_name>
      <phone>734-998-8400</phone>
      <email>mtmuller@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarosh</last_name>
      <phone>734-998-8400</phone>
      <email>csarosh@umich.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Nicolaas Bohnen, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Radiology and Neurology</investigator_title>
  </responsible_party>
  <keyword>Gait</keyword>
  <keyword>Balance</keyword>
  <keyword>GABA</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>PET Imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Mobility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

